The list covers orforglipron's US approval, ecnoglutide in China and Hanmi's efpeglenatide in Korea, with each asset's stage and best disclosed weight change.
Recap by typeshit. Full story at BioPharma APAC.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
Lincoln Journal Star reports FDA advisors are weighing whether seven unapproved peptides can be used in some compounded prescriptions.
Loading…